(en) Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et Toshihiko Doi, « Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors », Clinical Cancer Research, vol. 27, no 13, , p. 3620–3629 (ISSN1078-0432 et 1557-3265, DOI10.1158/1078-0432.CCR-20-4746, lire en ligne, consulté le )
(en) Stéphane Champiat, Laurent Dercle, Samy Ammari et Christophe Massard, « Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 », Clinical Cancer Research, vol. 23, no 8, , p. 1920–1928 (ISSN1078-0432 et 1557-3265, DOI10.1158/1078-0432.CCR-16-1741, lire en ligne, consulté le )
(en) Giuseppe Lo Russo, Massimo Moro, Michele Sommariva et Valeria Cancila, « Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade », Clinical Cancer Research, vol. 25, no 3, , p. 989–999 (ISSN1078-0432 et 1557-3265, DOI10.1158/1078-0432.CCR-18-1390, lire en ligne, consulté le )
(en) Katharine D. Grugan, Francis L. McCabe, Michelle Kinder et Allison R. Greenplate, « Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function », The Journal of Immunology, vol. 189, no 11, , p. 5457–5466 (ISSN0022-1767 et 1550-6606, DOI10.4049/jimmunol.1201889, lire en ligne, consulté le )
Manish J. Butte, Mary E. Keir, Theresa B. Phamduy et Arlene H. Sharpe, « Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses », Immunity, vol. 27, no 1, , p. 111–122 (ISSN1074-7613, PMID17629517, PMCIDPMC2707944, DOI10.1016/j.immuni.2007.05.016, lire en ligne, consulté le )
Nicholas L Syn, Michele W L Teng, Tony S K Mok et Ross A Soo, « De-novo and acquired resistance to immune checkpoint targeting », The Lancet Oncology, vol. 18, no 12, , e731–e741 (ISSN1470-2045, DOI10.1016/s1470-2045(17)30607-1, lire en ligne, consulté le )
L.V. Riella, A.M. Paterson, A.H. Sharpe et A. Chandraker, « Role of the PD-1 Pathway in the Immune Response », American Journal of Transplantation, vol. 12, no 10, , p. 2575–2587 (ISSN1600-6135, DOI10.1111/j.1600-6143.2012.04224.x, lire en ligne, consulté le )
(en) Qingyuan Huang, Yuzhen Zheng, Zhendong Gao et Lianxiong Yuan, « Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis », Journal of Cancer, vol. 12, no 4, , p. 1133–1143 (ISSN1837-9664, PMID33442411, PMCIDPMC7797652, DOI10.7150/jca.49325, lire en ligne, consulté le )
(en) Annika De Sousa Linhares, Claire Battin, Sabrina Jutz et Judith Leitner, « Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling », Scientific Reports, vol. 9, no 1, , p. 11472 (ISSN2045-2322, PMID31391510, PMCIDPMC6685986, DOI10.1038/s41598-019-47910-1, lire en ligne, consulté le )
(en) Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley et Lynette M. Sholl, « PD-L1 as a biomarker of response to immune-checkpoint inhibitors », Nature Reviews Clinical Oncology, vol. 18, no 6, , p. 345–362 (ISSN1759-4782, DOI10.1038/s41571-021-00473-5, lire en ligne, consulté le )
(en) Roy S. Herbst, Jean-Charles Soria, Marcin Kowanetz et Gregg D. Fine, « Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients », Nature, vol. 515, no 7528, , p. 563–567 (ISSN1476-4687, PMID25428504, PMCIDPMC4836193, DOI10.1038/nature14011, lire en ligne, consulté le )
(en) Haidong Dong, Gefeng Zhu, Koji Tamada et Lieping Chen, « B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion », Nature Medicine, vol. 5, no 12, , p. 1365–1369 (ISSN1546-170X, DOI10.1038/70932, lire en ligne, consulté le )
(en) Peter S. Linsley, Philip M. Wallace, Jennifer Johnson et Marylou G. Gibson, « Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule », Science, vol. 257, no 5071, , p. 792–795 (ISSN0036-8075 et 1095-9203, DOI10.1126/science.1496399, lire en ligne, consulté le )
Jackson G. Egen et James P. Allison, « Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength », Immunity, vol. 16, no 1, , p. 23–35 (ISSN1074-7613, DOI10.1016/s1074-7613(01)00259-x, lire en ligne, consulté le )
(en) Omar S. Qureshi, Yong Zheng, Kyoko Nakamura et Kesley Attridge, « Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 », Science, vol. 332, no 6029, , p. 600–603 (ISSN0036-8075 et 1095-9203, DOI10.1126/science.1202947, lire en ligne, consulté le )
(en) Marc A. Gavin, Jeffrey P. Rasmussen, Jason D. Fontenot et Valeria Vasta, « Foxp3-dependent programme of regulatory T-cell differentiation », Nature, vol. 445, no 7129, , p. 771–775 (ISSN1476-4687, DOI10.1038/nature05543, lire en ligne, consulté le )
Karl S. Peggs, Sergio A. Quezada, Cynthia A. Chambers et Alan J. Korman, « Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies », Journal of Experimental Medicine, vol. 206, no 8, , p. 1717–1725 (ISSN1540-9538 et 0022-1007, PMID19581407, PMCIDPMC2722174, DOI10.1084/jem.20082492, lire en ligne, consulté le )
(en) Luoyan Ai, Antao Xu et Jie Xu, « Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond », dans Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy, Springer, , 33–59 p. (ISBN978-981-15-3266-5, DOI10.1007/978-981-15-3266-5_3, lire en ligne)
(en) Hashem O. Alsaab, Samaresh Sau, Rami Alzhrani et Katyayani Tatiparti, « PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome », Frontiers in Pharmacology, vol. 8, (ISSN1663-9812, DOI10.3389/fphar.2017.00561, lire en ligne, consulté le )
(en) Loise M. Francisco, Victor H. Salinas, Keturah E. Brown, Vijay K. Vanguri, Gordon J. Freeman, Vijay K. Kuchroo, Arlene H. Sharpe, « PD-L1 regulates the development, maintenance, and function of induced regulatory T cells », J Exp Med, vol. 206, no 13, , p. 3015–3029 (DOI10.1084/jem.20090847, lire en ligne, consulté le )
Tadashi Yokosuka, Masako Takamatsu, Wakana Kobayashi-Imanishi et Akiko Hashimoto-Tane, « Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 », Journal of Experimental Medicine, vol. 209, no 6, , p. 1201–1217 (ISSN1540-9538 et 0022-1007, PMID22641383, PMCIDPMC3371732, DOI10.1084/jem.20112741, lire en ligne, consulté le )
Tetsuya Honda, Jackson G. Egen, Tim Lämmermann et Wolfgang Kastenmüller, « Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues », Immunity, vol. 40, no 2, , p. 235–247 (ISSN1074-7613, PMID24440150, PMCIDPMC4792276, DOI10.1016/j.immuni.2013.11.017, lire en ligne, consulté le )
Yoshihiro Komohara, Yukio Fujiwara, Koji Ohnishi et Motohiro Takeya, « Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy », Advanced Drug Delivery Reviews, vol. 99, , p. 180–185 (ISSN0169-409X, DOI10.1016/j.addr.2015.11.009, lire en ligne, consulté le )
(en) Karen O. Dixon, Marcin Tabaka, Markus A. Schramm et Sheng Xiao, « TIM-3 restrains anti-tumour immunity by regulating inflammasome activation », Nature, vol. 595, no 7865, , p. 101–106 (ISSN1476-4687, DOI10.1038/s41586-021-03626-9, lire en ligne, consulté le )
(en) Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et Toshihiko Doi, « Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors », Clinical Cancer Research, vol. 27, no 13, , p. 3620–3629 (ISSN1078-0432 et 1557-3265, DOI10.1158/1078-0432.CCR-20-4746, lire en ligne, consulté le )
(en) Abbas Shapouri‐Moghaddam, Saeed Mohammadian, Hossein Vazini et Mahdi Taghadosi, « Macrophage plasticity, polarization, and function in health and disease », Journal of Cellular Physiology, vol. 233, no 9, , p. 6425–6440 (ISSN0021-9541 et 1097-4652, DOI10.1002/jcp.26429, lire en ligne, consulté le )
(en) Katharine D. Grugan, Francis L. McCabe, Michelle Kinder et Allison R. Greenplate, « Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function », The Journal of Immunology, vol. 189, no 11, , p. 5457–5466 (ISSN0022-1767 et 1550-6606, DOI10.4049/jimmunol.1201889, lire en ligne, consulté le )
André Veillette et Jun Chen, « SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy », Trends in Immunology, vol. 39, no 3, , p. 173–184 (ISSN1471-4906, DOI10.1016/j.it.2017.12.005, lire en ligne, consulté le )
(en) Cory Alvey, Dennis E Discher, « Engineering macrophages to eat cancer: from “marker of self” CD47 and phagocytosis to differentiation », Journal of Leukocyte Biology, vol. 102, no 1, , p. 31–40 (DOI10.1189/jlb.4ri1216-516r, lire en ligne, consulté le )
(en) Hanke L. Matlung, Katka Szilagyi, Neil A. Barclay et Timo K. van den Berg, « The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer », Immunological Reviews, vol. 276, no 1, , p. 145–164 (ISSN0105-2896 et 1600-065X, DOI10.1111/imr.12527, lire en ligne, consulté le )
(en) Elvire Pons-Tostivint, Aurélien Latouche, Pauline Vaflard, Francesco Ricci, Delphine Loirat, Ségolène Hescot, Marie-Paule Sablin, Roman Rouzier, Maud Kamal, Claire Morel, Charlotte Lecerf, Vincent Servois, Xavier Paolett & Christophe Le Tourneau, MD, PhD, « Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials », JCO Precision Oncology, (DOI10.1200/PO.18.00114).
(en) Michael A. Postow, Robert Sidlow et Matthew D. Hellmann, « Immune-Related Adverse Events Associated with Immune Checkpoint Blockade », New England Journal of Medicine, vol. 378, no 2, , p. 158–168 (ISSN0028-4793 et 1533-4406, DOI10.1056/nejmra1703481, lire en ligne, consulté le )
Syed Hussaini, Rania Chehade, Ronald Gabriel Boldt et Jacques Raphael, « Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis », Cancer Treatment Reviews, vol. 92, , p. 102134 (ISSN1532-1967, PMID33302134, DOI10.1016/j.ctrv.2020.102134, lire en ligne, consulté le ).
Joseph M. Unger, Riha Vaidya, Kathy S. Albain et Michael LeBlanc, « Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials », Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 40, no 13, , p. 1474–1486 (ISSN1527-7755, PMID35119908, PMCID9061143, DOI10.1200/JCO.21.02377, lire en ligne, consulté le ).
(en) Morgane Denis, Michael Duruisseaux, Marie Brevet et Charles Dumontet, « How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? », Frontiers in Immunology, vol. 11, (ISSN1664-3224, DOI10.3389/fimmu.2020.00492, lire en ligne, consulté le )
(en) Shotaro Chubachi, Hiroyuki Yasuda, Hidehiro Irie et Koichi Fukunaga, « A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment », Case Reports in Oncological Medicine, vol. 2016, , e1075641 (ISSN2090-6706, PMID28116195, PMCIDPMC5223009, DOI10.1155/2016/1075641, lire en ligne, consulté le )
(en) Stéphane Champiat, Laurent Dercle, Samy Ammari et Christophe Massard, « Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 », Clinical Cancer Research, vol. 23, no 8, , p. 1920–1928 (ISSN1078-0432 et 1557-3265, DOI10.1158/1078-0432.CCR-16-1741, lire en ligne, consulté le )
(en) Giuseppe Lo Russo, Massimo Moro, Michele Sommariva et Valeria Cancila, « Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade », Clinical Cancer Research, vol. 25, no 3, , p. 989–999 (ISSN1078-0432 et 1557-3265, DOI10.1158/1078-0432.CCR-18-1390, lire en ligne, consulté le )
(en) Xueping Wang, Fang Wang, Mengjun Zhong et Yosef Yarden, « The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy », Molecular Cancer, vol. 19, no 1, , p. 81 (ISSN1476-4598, DOI10.1186/s12943-020-01200-x, lire en ligne, consulté le )
(en) Dennis Ledford, William Busse, Benjamin Trzaskoma, Theodore A. Omachi, Karin Rosén, Bradley E. Chipps, Allan T. Luskin et Paul G. Solari, « A randomized multicenter study evaluating Xolair persistence of response after long-term therapy », The Journal of Allergy and Clinical Immunology, , p. 162-169 (DOI10.1016/j.jaci.2016.08.054, lire en ligne).
Simone Camelliti, Valentino Le Noci, Francesca Bianchi et Claudia Moscheni, « Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know », Journal of Experimental & Clinical Cancer Research, vol. 39, no 1, , p. 236 (ISSN1756-9966, PMID33168050, PMCIDPMC7650183, DOI10.1186/s13046-020-01721-9, lire en ligne, consulté le )
Manish J. Butte, Mary E. Keir, Theresa B. Phamduy et Arlene H. Sharpe, « Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses », Immunity, vol. 27, no 1, , p. 111–122 (ISSN1074-7613, PMID17629517, PMCIDPMC2707944, DOI10.1016/j.immuni.2007.05.016, lire en ligne, consulté le )
Nicholas L Syn, Michele W L Teng, Tony S K Mok et Ross A Soo, « De-novo and acquired resistance to immune checkpoint targeting », The Lancet Oncology, vol. 18, no 12, , e731–e741 (ISSN1470-2045, DOI10.1016/s1470-2045(17)30607-1, lire en ligne, consulté le )
L.V. Riella, A.M. Paterson, A.H. Sharpe et A. Chandraker, « Role of the PD-1 Pathway in the Immune Response », American Journal of Transplantation, vol. 12, no 10, , p. 2575–2587 (ISSN1600-6135, DOI10.1111/j.1600-6143.2012.04224.x, lire en ligne, consulté le )
Jackson G. Egen et James P. Allison, « Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength », Immunity, vol. 16, no 1, , p. 23–35 (ISSN1074-7613, DOI10.1016/s1074-7613(01)00259-x, lire en ligne, consulté le )
Karl S. Peggs, Sergio A. Quezada, Cynthia A. Chambers et Alan J. Korman, « Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies », Journal of Experimental Medicine, vol. 206, no 8, , p. 1717–1725 (ISSN1540-9538 et 0022-1007, PMID19581407, PMCIDPMC2722174, DOI10.1084/jem.20082492, lire en ligne, consulté le )
(en) Luoyan Ai, Antao Xu et Jie Xu, « Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond », dans Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy, Springer, , 33–59 p. (ISBN978-981-15-3266-5, DOI10.1007/978-981-15-3266-5_3, lire en ligne)
Tadashi Yokosuka, Masako Takamatsu, Wakana Kobayashi-Imanishi et Akiko Hashimoto-Tane, « Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 », Journal of Experimental Medicine, vol. 209, no 6, , p. 1201–1217 (ISSN1540-9538 et 0022-1007, PMID22641383, PMCIDPMC3371732, DOI10.1084/jem.20112741, lire en ligne, consulté le )
Tetsuya Honda, Jackson G. Egen, Tim Lämmermann et Wolfgang Kastenmüller, « Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues », Immunity, vol. 40, no 2, , p. 235–247 (ISSN1074-7613, PMID24440150, PMCIDPMC4792276, DOI10.1016/j.immuni.2013.11.017, lire en ligne, consulté le )
Yoshihiro Komohara, Yukio Fujiwara, Koji Ohnishi et Motohiro Takeya, « Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy », Advanced Drug Delivery Reviews, vol. 99, , p. 180–185 (ISSN0169-409X, DOI10.1016/j.addr.2015.11.009, lire en ligne, consulté le )
André Veillette et Jun Chen, « SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy », Trends in Immunology, vol. 39, no 3, , p. 173–184 (ISSN1471-4906, DOI10.1016/j.it.2017.12.005, lire en ligne, consulté le )
(en) Michael A. Postow, Robert Sidlow et Matthew D. Hellmann, « Immune-Related Adverse Events Associated with Immune Checkpoint Blockade », New England Journal of Medicine, vol. 378, no 2, , p. 158–168 (ISSN0028-4793 et 1533-4406, DOI10.1056/nejmra1703481, lire en ligne, consulté le )
(en) Xueping Wang, Fang Wang, Mengjun Zhong et Yosef Yarden, « The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy », Molecular Cancer, vol. 19, no 1, , p. 81 (ISSN1476-4598, DOI10.1186/s12943-020-01200-x, lire en ligne, consulté le )
Simone Camelliti, Valentino Le Noci, Francesca Bianchi et Claudia Moscheni, « Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know », Journal of Experimental & Clinical Cancer Research, vol. 39, no 1, , p. 236 (ISSN1756-9966, PMID33168050, PMCIDPMC7650183, DOI10.1186/s13046-020-01721-9, lire en ligne, consulté le )
(en) Hashem O. Alsaab, Samaresh Sau, Rami Alzhrani et Katyayani Tatiparti, « PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome », Frontiers in Pharmacology, vol. 8, (ISSN1663-9812, DOI10.3389/fphar.2017.00561, lire en ligne, consulté le )
(en) Morgane Denis, Michael Duruisseaux, Marie Brevet et Charles Dumontet, « How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? », Frontiers in Immunology, vol. 11, (ISSN1664-3224, DOI10.3389/fimmu.2020.00492, lire en ligne, consulté le )
hindawi.com
(en) Shotaro Chubachi, Hiroyuki Yasuda, Hidehiro Irie et Koichi Fukunaga, « A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment », Case Reports in Oncological Medicine, vol. 2016, , e1075641 (ISSN2090-6706, PMID28116195, PMCIDPMC5223009, DOI10.1155/2016/1075641, lire en ligne, consulté le )
Manish J. Butte, Mary E. Keir, Theresa B. Phamduy et Arlene H. Sharpe, « Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses », Immunity, vol. 27, no 1, , p. 111–122 (ISSN1074-7613, PMID17629517, PMCIDPMC2707944, DOI10.1016/j.immuni.2007.05.016, lire en ligne, consulté le )
Nicholas L Syn, Michele W L Teng, Tony S K Mok et Ross A Soo, « De-novo and acquired resistance to immune checkpoint targeting », The Lancet Oncology, vol. 18, no 12, , e731–e741 (ISSN1470-2045, DOI10.1016/s1470-2045(17)30607-1, lire en ligne, consulté le )
L.V. Riella, A.M. Paterson, A.H. Sharpe et A. Chandraker, « Role of the PD-1 Pathway in the Immune Response », American Journal of Transplantation, vol. 12, no 10, , p. 2575–2587 (ISSN1600-6135, DOI10.1111/j.1600-6143.2012.04224.x, lire en ligne, consulté le )
Yanyan Han, Dandan Liu et Lianhong Li, « PD-1/PD-L1 pathway: current researches in cancer », American Journal of Cancer Research, vol. 10, no 3, , p. 727–742 (ISSN2156-6976, PMID32266087, PMCID7136921, lire en ligne, consulté le )
(en) Qingyuan Huang, Yuzhen Zheng, Zhendong Gao et Lianxiong Yuan, « Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis », Journal of Cancer, vol. 12, no 4, , p. 1133–1143 (ISSN1837-9664, PMID33442411, PMCIDPMC7797652, DOI10.7150/jca.49325, lire en ligne, consulté le )
(en) Annika De Sousa Linhares, Claire Battin, Sabrina Jutz et Judith Leitner, « Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling », Scientific Reports, vol. 9, no 1, , p. 11472 (ISSN2045-2322, PMID31391510, PMCIDPMC6685986, DOI10.1038/s41598-019-47910-1, lire en ligne, consulté le )
(en) Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley et Lynette M. Sholl, « PD-L1 as a biomarker of response to immune-checkpoint inhibitors », Nature Reviews Clinical Oncology, vol. 18, no 6, , p. 345–362 (ISSN1759-4782, DOI10.1038/s41571-021-00473-5, lire en ligne, consulté le )
(en) Roy S. Herbst, Jean-Charles Soria, Marcin Kowanetz et Gregg D. Fine, « Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients », Nature, vol. 515, no 7528, , p. 563–567 (ISSN1476-4687, PMID25428504, PMCIDPMC4836193, DOI10.1038/nature14011, lire en ligne, consulté le )
(en) Haidong Dong, Gefeng Zhu, Koji Tamada et Lieping Chen, « B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion », Nature Medicine, vol. 5, no 12, , p. 1365–1369 (ISSN1546-170X, DOI10.1038/70932, lire en ligne, consulté le )
(en) Peter S. Linsley, Philip M. Wallace, Jennifer Johnson et Marylou G. Gibson, « Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule », Science, vol. 257, no 5071, , p. 792–795 (ISSN0036-8075 et 1095-9203, DOI10.1126/science.1496399, lire en ligne, consulté le )
Jackson G. Egen et James P. Allison, « Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength », Immunity, vol. 16, no 1, , p. 23–35 (ISSN1074-7613, DOI10.1016/s1074-7613(01)00259-x, lire en ligne, consulté le )
(en) Omar S. Qureshi, Yong Zheng, Kyoko Nakamura et Kesley Attridge, « Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 », Science, vol. 332, no 6029, , p. 600–603 (ISSN0036-8075 et 1095-9203, DOI10.1126/science.1202947, lire en ligne, consulté le )
(en) Marc A. Gavin, Jeffrey P. Rasmussen, Jason D. Fontenot et Valeria Vasta, « Foxp3-dependent programme of regulatory T-cell differentiation », Nature, vol. 445, no 7129, , p. 771–775 (ISSN1476-4687, DOI10.1038/nature05543, lire en ligne, consulté le )
Karl S. Peggs, Sergio A. Quezada, Cynthia A. Chambers et Alan J. Korman, « Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies », Journal of Experimental Medicine, vol. 206, no 8, , p. 1717–1725 (ISSN1540-9538 et 0022-1007, PMID19581407, PMCIDPMC2722174, DOI10.1084/jem.20082492, lire en ligne, consulté le )
(en) Hashem O. Alsaab, Samaresh Sau, Rami Alzhrani et Katyayani Tatiparti, « PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome », Frontiers in Pharmacology, vol. 8, (ISSN1663-9812, DOI10.3389/fphar.2017.00561, lire en ligne, consulté le )
Tadashi Yokosuka, Masako Takamatsu, Wakana Kobayashi-Imanishi et Akiko Hashimoto-Tane, « Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 », Journal of Experimental Medicine, vol. 209, no 6, , p. 1201–1217 (ISSN1540-9538 et 0022-1007, PMID22641383, PMCIDPMC3371732, DOI10.1084/jem.20112741, lire en ligne, consulté le )
Tetsuya Honda, Jackson G. Egen, Tim Lämmermann et Wolfgang Kastenmüller, « Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues », Immunity, vol. 40, no 2, , p. 235–247 (ISSN1074-7613, PMID24440150, PMCIDPMC4792276, DOI10.1016/j.immuni.2013.11.017, lire en ligne, consulté le )
Yoshihiro Komohara, Yukio Fujiwara, Koji Ohnishi et Motohiro Takeya, « Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy », Advanced Drug Delivery Reviews, vol. 99, , p. 180–185 (ISSN0169-409X, DOI10.1016/j.addr.2015.11.009, lire en ligne, consulté le )
(en) Karen O. Dixon, Marcin Tabaka, Markus A. Schramm et Sheng Xiao, « TIM-3 restrains anti-tumour immunity by regulating inflammasome activation », Nature, vol. 595, no 7865, , p. 101–106 (ISSN1476-4687, DOI10.1038/s41586-021-03626-9, lire en ligne, consulté le )
(en) Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et Toshihiko Doi, « Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors », Clinical Cancer Research, vol. 27, no 13, , p. 3620–3629 (ISSN1078-0432 et 1557-3265, DOI10.1158/1078-0432.CCR-20-4746, lire en ligne, consulté le )
(en) Abbas Shapouri‐Moghaddam, Saeed Mohammadian, Hossein Vazini et Mahdi Taghadosi, « Macrophage plasticity, polarization, and function in health and disease », Journal of Cellular Physiology, vol. 233, no 9, , p. 6425–6440 (ISSN0021-9541 et 1097-4652, DOI10.1002/jcp.26429, lire en ligne, consulté le )
(en) Katharine D. Grugan, Francis L. McCabe, Michelle Kinder et Allison R. Greenplate, « Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function », The Journal of Immunology, vol. 189, no 11, , p. 5457–5466 (ISSN0022-1767 et 1550-6606, DOI10.4049/jimmunol.1201889, lire en ligne, consulté le )
André Veillette et Jun Chen, « SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy », Trends in Immunology, vol. 39, no 3, , p. 173–184 (ISSN1471-4906, DOI10.1016/j.it.2017.12.005, lire en ligne, consulté le )
(en) Hanke L. Matlung, Katka Szilagyi, Neil A. Barclay et Timo K. van den Berg, « The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer », Immunological Reviews, vol. 276, no 1, , p. 145–164 (ISSN0105-2896 et 1600-065X, DOI10.1111/imr.12527, lire en ligne, consulté le )
(en) Michael A. Postow, Robert Sidlow et Matthew D. Hellmann, « Immune-Related Adverse Events Associated with Immune Checkpoint Blockade », New England Journal of Medicine, vol. 378, no 2, , p. 158–168 (ISSN0028-4793 et 1533-4406, DOI10.1056/nejmra1703481, lire en ligne, consulté le )
Syed Hussaini, Rania Chehade, Ronald Gabriel Boldt et Jacques Raphael, « Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis », Cancer Treatment Reviews, vol. 92, , p. 102134 (ISSN1532-1967, PMID33302134, DOI10.1016/j.ctrv.2020.102134, lire en ligne, consulté le ).
Joseph M. Unger, Riha Vaidya, Kathy S. Albain et Michael LeBlanc, « Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials », Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 40, no 13, , p. 1474–1486 (ISSN1527-7755, PMID35119908, PMCID9061143, DOI10.1200/JCO.21.02377, lire en ligne, consulté le ).
(en) Morgane Denis, Michael Duruisseaux, Marie Brevet et Charles Dumontet, « How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? », Frontiers in Immunology, vol. 11, (ISSN1664-3224, DOI10.3389/fimmu.2020.00492, lire en ligne, consulté le )
(en) Shotaro Chubachi, Hiroyuki Yasuda, Hidehiro Irie et Koichi Fukunaga, « A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment », Case Reports in Oncological Medicine, vol. 2016, , e1075641 (ISSN2090-6706, PMID28116195, PMCIDPMC5223009, DOI10.1155/2016/1075641, lire en ligne, consulté le )
(en) Stéphane Champiat, Laurent Dercle, Samy Ammari et Christophe Massard, « Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 », Clinical Cancer Research, vol. 23, no 8, , p. 1920–1928 (ISSN1078-0432 et 1557-3265, DOI10.1158/1078-0432.CCR-16-1741, lire en ligne, consulté le )
(en) Giuseppe Lo Russo, Massimo Moro, Michele Sommariva et Valeria Cancila, « Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade », Clinical Cancer Research, vol. 25, no 3, , p. 989–999 (ISSN1078-0432 et 1557-3265, DOI10.1158/1078-0432.CCR-18-1390, lire en ligne, consulté le )
(en) Xueping Wang, Fang Wang, Mengjun Zhong et Yosef Yarden, « The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy », Molecular Cancer, vol. 19, no 1, , p. 81 (ISSN1476-4598, DOI10.1186/s12943-020-01200-x, lire en ligne, consulté le )
Simone Camelliti, Valentino Le Noci, Francesca Bianchi et Claudia Moscheni, « Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know », Journal of Experimental & Clinical Cancer Research, vol. 39, no 1, , p. 236 (ISSN1756-9966, PMID33168050, PMCIDPMC7650183, DOI10.1186/s13046-020-01721-9, lire en ligne, consulté le )
jcancer.org
(en) Qingyuan Huang, Yuzhen Zheng, Zhendong Gao et Lianxiong Yuan, « Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis », Journal of Cancer, vol. 12, no 4, , p. 1133–1143 (ISSN1837-9664, PMID33442411, PMCIDPMC7797652, DOI10.7150/jca.49325, lire en ligne, consulté le )
(en) Annika De Sousa Linhares, Claire Battin, Sabrina Jutz et Judith Leitner, « Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling », Scientific Reports, vol. 9, no 1, , p. 11472 (ISSN2045-2322, PMID31391510, PMCIDPMC6685986, DOI10.1038/s41598-019-47910-1, lire en ligne, consulté le )
(en) Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley et Lynette M. Sholl, « PD-L1 as a biomarker of response to immune-checkpoint inhibitors », Nature Reviews Clinical Oncology, vol. 18, no 6, , p. 345–362 (ISSN1759-4782, DOI10.1038/s41571-021-00473-5, lire en ligne, consulté le )
(en) Roy S. Herbst, Jean-Charles Soria, Marcin Kowanetz et Gregg D. Fine, « Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients », Nature, vol. 515, no 7528, , p. 563–567 (ISSN1476-4687, PMID25428504, PMCIDPMC4836193, DOI10.1038/nature14011, lire en ligne, consulté le )
(en) Haidong Dong, Gefeng Zhu, Koji Tamada et Lieping Chen, « B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion », Nature Medicine, vol. 5, no 12, , p. 1365–1369 (ISSN1546-170X, DOI10.1038/70932, lire en ligne, consulté le )
(en) Marc A. Gavin, Jeffrey P. Rasmussen, Jason D. Fontenot et Valeria Vasta, « Foxp3-dependent programme of regulatory T-cell differentiation », Nature, vol. 445, no 7129, , p. 771–775 (ISSN1476-4687, DOI10.1038/nature05543, lire en ligne, consulté le )
(en) Karen O. Dixon, Marcin Tabaka, Markus A. Schramm et Sheng Xiao, « TIM-3 restrains anti-tumour immunity by regulating inflammasome activation », Nature, vol. 595, no 7865, , p. 101–106 (ISSN1476-4687, DOI10.1038/s41586-021-03626-9, lire en ligne, consulté le )
Manish J. Butte, Mary E. Keir, Theresa B. Phamduy et Arlene H. Sharpe, « Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses », Immunity, vol. 27, no 1, , p. 111–122 (ISSN1074-7613, PMID17629517, PMCIDPMC2707944, DOI10.1016/j.immuni.2007.05.016, lire en ligne, consulté le )
Yanyan Han, Dandan Liu et Lianhong Li, « PD-1/PD-L1 pathway: current researches in cancer », American Journal of Cancer Research, vol. 10, no 3, , p. 727–742 (ISSN2156-6976, PMID32266087, PMCID7136921, lire en ligne, consulté le )
(en) Qingyuan Huang, Yuzhen Zheng, Zhendong Gao et Lianxiong Yuan, « Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis », Journal of Cancer, vol. 12, no 4, , p. 1133–1143 (ISSN1837-9664, PMID33442411, PMCIDPMC7797652, DOI10.7150/jca.49325, lire en ligne, consulté le )
(en) Annika De Sousa Linhares, Claire Battin, Sabrina Jutz et Judith Leitner, « Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling », Scientific Reports, vol. 9, no 1, , p. 11472 (ISSN2045-2322, PMID31391510, PMCIDPMC6685986, DOI10.1038/s41598-019-47910-1, lire en ligne, consulté le )
(en) Roy S. Herbst, Jean-Charles Soria, Marcin Kowanetz et Gregg D. Fine, « Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients », Nature, vol. 515, no 7528, , p. 563–567 (ISSN1476-4687, PMID25428504, PMCIDPMC4836193, DOI10.1038/nature14011, lire en ligne, consulté le )
Karl S. Peggs, Sergio A. Quezada, Cynthia A. Chambers et Alan J. Korman, « Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies », Journal of Experimental Medicine, vol. 206, no 8, , p. 1717–1725 (ISSN1540-9538 et 0022-1007, PMID19581407, PMCIDPMC2722174, DOI10.1084/jem.20082492, lire en ligne, consulté le )
Tadashi Yokosuka, Masako Takamatsu, Wakana Kobayashi-Imanishi et Akiko Hashimoto-Tane, « Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 », Journal of Experimental Medicine, vol. 209, no 6, , p. 1201–1217 (ISSN1540-9538 et 0022-1007, PMID22641383, PMCIDPMC3371732, DOI10.1084/jem.20112741, lire en ligne, consulté le )
Tetsuya Honda, Jackson G. Egen, Tim Lämmermann et Wolfgang Kastenmüller, « Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues », Immunity, vol. 40, no 2, , p. 235–247 (ISSN1074-7613, PMID24440150, PMCIDPMC4792276, DOI10.1016/j.immuni.2013.11.017, lire en ligne, consulté le )
Syed Hussaini, Rania Chehade, Ronald Gabriel Boldt et Jacques Raphael, « Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis », Cancer Treatment Reviews, vol. 92, , p. 102134 (ISSN1532-1967, PMID33302134, DOI10.1016/j.ctrv.2020.102134, lire en ligne, consulté le ).
Joseph M. Unger, Riha Vaidya, Kathy S. Albain et Michael LeBlanc, « Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials », Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 40, no 13, , p. 1474–1486 (ISSN1527-7755, PMID35119908, PMCID9061143, DOI10.1200/JCO.21.02377, lire en ligne, consulté le ).
(en) Shotaro Chubachi, Hiroyuki Yasuda, Hidehiro Irie et Koichi Fukunaga, « A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment », Case Reports in Oncological Medicine, vol. 2016, , e1075641 (ISSN2090-6706, PMID28116195, PMCIDPMC5223009, DOI10.1155/2016/1075641, lire en ligne, consulté le )
Simone Camelliti, Valentino Le Noci, Francesca Bianchi et Claudia Moscheni, « Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know », Journal of Experimental & Clinical Cancer Research, vol. 39, no 1, , p. 236 (ISSN1756-9966, PMID33168050, PMCIDPMC7650183, DOI10.1186/s13046-020-01721-9, lire en ligne, consulté le )
pubmed.ncbi.nlm.nih.gov
Yanyan Han, Dandan Liu et Lianhong Li, « PD-1/PD-L1 pathway: current researches in cancer », American Journal of Cancer Research, vol. 10, no 3, , p. 727–742 (ISSN2156-6976, PMID32266087, PMCID7136921, lire en ligne, consulté le )
Syed Hussaini, Rania Chehade, Ronald Gabriel Boldt et Jacques Raphael, « Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis », Cancer Treatment Reviews, vol. 92, , p. 102134 (ISSN1532-1967, PMID33302134, DOI10.1016/j.ctrv.2020.102134, lire en ligne, consulté le ).
Joseph M. Unger, Riha Vaidya, Kathy S. Albain et Michael LeBlanc, « Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials », Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 40, no 13, , p. 1474–1486 (ISSN1527-7755, PMID35119908, PMCID9061143, DOI10.1200/JCO.21.02377, lire en ligne, consulté le ).
(en) Dennis Ledford, William Busse, Benjamin Trzaskoma, Theodore A. Omachi, Karin Rosén, Bradley E. Chipps, Allan T. Luskin et Paul G. Solari, « A randomized multicenter study evaluating Xolair persistence of response after long-term therapy », The Journal of Allergy and Clinical Immunology, , p. 162-169 (DOI10.1016/j.jaci.2016.08.054, lire en ligne).
(en) Cory Alvey, Dennis E Discher, « Engineering macrophages to eat cancer: from “marker of self” CD47 and phagocytosis to differentiation », Journal of Leukocyte Biology, vol. 102, no 1, , p. 31–40 (DOI10.1189/jlb.4ri1216-516r, lire en ligne, consulté le )
rupress.org
(en) Loise M. Francisco, Victor H. Salinas, Keturah E. Brown, Vijay K. Vanguri, Gordon J. Freeman, Vijay K. Kuchroo, Arlene H. Sharpe, « PD-L1 regulates the development, maintenance, and function of induced regulatory T cells », J Exp Med, vol. 206, no 13, , p. 3015–3029 (DOI10.1084/jem.20090847, lire en ligne, consulté le )
science.org
(en) Peter S. Linsley, Philip M. Wallace, Jennifer Johnson et Marylou G. Gibson, « Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule », Science, vol. 257, no 5071, , p. 792–795 (ISSN0036-8075 et 1095-9203, DOI10.1126/science.1496399, lire en ligne, consulté le )
(en) Omar S. Qureshi, Yong Zheng, Kyoko Nakamura et Kesley Attridge, « Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 », Science, vol. 332, no 6029, , p. 600–603 (ISSN0036-8075 et 1095-9203, DOI10.1126/science.1202947, lire en ligne, consulté le )
(en) Abbas Shapouri‐Moghaddam, Saeed Mohammadian, Hossein Vazini et Mahdi Taghadosi, « Macrophage plasticity, polarization, and function in health and disease », Journal of Cellular Physiology, vol. 233, no 9, , p. 6425–6440 (ISSN0021-9541 et 1097-4652, DOI10.1002/jcp.26429, lire en ligne, consulté le )
(en) Hanke L. Matlung, Katka Szilagyi, Neil A. Barclay et Timo K. van den Berg, « The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer », Immunological Reviews, vol. 276, no 1, , p. 145–164 (ISSN0105-2896 et 1600-065X, DOI10.1111/imr.12527, lire en ligne, consulté le )